Cardioprotective Effects of GLP-1 and Their Mechanisms
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Ischaemic heart disease is the most common cause of death in the UK. Glucagon-like peptide-1
(GLP-1) has been demonstrated to protect the heart when it is deprived of blood supply
(ischaemia). The mechanism for this protection is not clear. Similar protection occurs with
ischaemic conditioning of the heart, which is dependent on potassium channel opening.
The investigators intend to establish whether GLP-1 mediated protection shares a similar
mechanistic pathway. In order to do this the investigators will measures pressure--volume
loops generated in the main pumping chamber of the heart at the time of a percutaneous
coronary intervention (stenting). Patients will be allocated to GLP-1 alone, GLP-1 with
glibenclamide (a potassium channel blocking medication approved for human use), saline
control or glibenclamide alone.
The investigators hypothesis is that the effect of GLP-1 will be abrogated by use of
glibenclamide.